Viridian Therapeutics, Inc. (VRDN)
30.48
-0.77
(-2.46%)
USD |
NASDAQ |
Nov 12, 16:00
30.46
-0.02
(-0.05%)
After-Hours: 20:00
Viridian Therapeutics Free Cash Flow (Quarterly) : -93.14M for Sept. 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -93.14M |
| June 30, 2026 | -106.63M |
| March 31, 2026 | -119.68M |
| December 31, 2025 | -24.47M |
| September 30, 2025 | -84.74M |
| June 30, 2025 | -75.42M |
| March 31, 2025 | -92.74M |
| December 31, 2024 | -73.45M |
| September 30, 2024 | -68.00M |
| June 30, 2024 | -46.16M |
| March 31, 2024 | -45.22M |
| December 31, 2023 | -38.05M |
| September 30, 2023 | -39.39M |
| June 30, 2023 | -45.54M |
| March 31, 2023 | -62.09M |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | -18.38M |
| March 31, 2022 | -21.22M |
| December 31, 2021 | -16.62M |
| September 30, 2021 | -12.06M |
| June 30, 2021 | -14.68M |
| March 31, 2021 | -11.55M |
| December 31, 2020 | -9.425M |
| September 30, 2020 | -5.148M |
| Date | Value |
|---|---|
| June 30, 2020 | -6.789M |
| March 31, 2020 | -8.459M |
| December 31, 2019 | -7.806M |
| September 30, 2019 | -9.282M |
| June 30, 2019 | -7.206M |
| March 31, 2019 | -11.85M |
| December 31, 2018 | -8.226M |
| September 30, 2018 | -7.007M |
| June 30, 2018 | -4.60M |
| March 31, 2018 | -7.456M |
| December 31, 2017 | -7.277M |
| September 30, 2017 | -5.726M |
| June 30, 2017 | -7.183M |
| March 31, 2017 | -8.227M |
| December 31, 2016 | -3.297M |
| September 30, 2016 | -7.475M |
| June 30, 2016 | -2.008M |
| March 31, 2016 | -2.225M |
| December 31, 2015 | -1.322M |
| September 30, 2015 | -2.336M |
| June 30, 2015 | -2.21M |
| March 31, 2015 | -1.153M |
| December 31, 2014 | -1.258M |
| September 30, 2014 | -0.831M |
| June 30, 2014 |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Travere Therapeutics, Inc. | 69.45M |
| Vertex Pharmaceuticals, Inc. | 545.80M |
| TG Therapeutics, Inc. | 44.94M |
| ACADIA Pharmaceuticals, Inc. | 10.26M |
| Alnylam Pharmaceuticals, Inc. | 271.15M |